Safety and efficacy of menatetrenone in children with osteogenesis imperfecta

1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004; 363:1377-85.10.1016/S0140-6736(04)16051-0Open DOISearch in Google Scholar

2. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000; 26:581-9.10.1016/S8756-3282(00)00269-6Open DOISearch in Google Scholar

3. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab. 2006; 91:511-6.10.1210/jc.2005-2036Open DOISearch in Google Scholar

4. Vallo A, Rodriguez-Leyva F, Rodriguez Soriano J. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr. 2006; 95:332-9.10.1080/08035250500434785Open DOISearch in Google Scholar

5. Brown JJ, Zacharin MR. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab. 2009; 22:55-63.10.1515/JPEM.2009.22.1.55Open DOISearch in Google Scholar

6. Marini JC. Bone: Use of bisphosphonates in childrenproceed with caution. Nat Rev Endocrinol. 2009; 5: 241-3.10.1038/nrendo.2009.58Open DOISearch in Google Scholar

7. Zittermann A. Effects of vitamin K on calcium and bone metabolism. Curr Opin Clin Nutr Metab Care. 2001; 4: 483-7.10.1097/00075197-200111000-00003Open DOISearch in Google Scholar

8. Kaneki M, Hosoi T, Ouchi Y, Orimo H. Pleiotropic actions of vitamin K: protector of bone health and beyond? Nutrition. 2006; 22:845-52.10.1016/j.nut.2006.05.003Open DOISearch in Google Scholar

9. Hodges SJ, Pilkington MJ, Stamp TC, Catterall A, Shearer MJ, Bitensky L, et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone. 1991; 12:387-9.10.1016/8756-3282(91)90027-GOpen DOISearch in Google Scholar

10. Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res. 1993; 8:1241-5.10.1002/jbmr.56500810128256661Open DOISearch in Google Scholar

11. Tamatani M, Morimoto S, Nakajima M, Fukuo K, Onishi T, Kitano S, et al. Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men. Metabolism. 1998; 47:195-9.10.1016/S0026-0495(98)90220-7Open DOISearch in Google Scholar

12. Booth SL, Broe KE, Peterson JW, Cheng DM, Dawson- Hughes B, Gundberg CM, et al. Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab. 2004; 89:4904-9.10.1210/jc.2003-03167315472183Open DOISearch in Google Scholar

13. Hauschka PV, Lian JB, Gallop PM. Direct identification of the calcium-binding amino acid, gammacarboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA. 1975; 72:3925-9.10.1073/pnas.72.10.39254331091060074Open DOISearch in Google Scholar

14. Price PA, Otsuka AA, Poser JW, Kristaponis J, Raman N. Characterization of a gamma-carboxyglutamic acidcontaining protein from bone. Proc Natl Acad Sci USA. 1976; 73:1447-51.10.1073/pnas.73.5.14474303131064018Open DOISearch in Google Scholar

15. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000; 15:515-21.10.1359/jbmr.2000.15.3.51510750566Open DOISearch in Google Scholar

16. Bunyaratavej N, Penkitti P, Kittimanon N, Boonsangsom P, Bonjongsat A, Yunoi S. Efficacy and safety of Menatetrenone-4 postmenopausal Thai women. J Med Assoc Thai. 2001; 84 Suppl 2:S553-9.Search in Google Scholar

17. Iwamoto J, Takeda T, Ichimura S. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci. 2001; 6:487-92.10.1007/s00776010000211793169Open DOISearch in Google Scholar

18. Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, Nakamura T, et al. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab. 2009; 27:66-75.10.1007/s00774-008-0008-819082528Open DOISearch in Google Scholar

19. Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina- Granade G, Duboeuf F, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006; 21:300-6.10.1359/JBMR.05101516418786Search in Google Scholar